Cadrenal Therapeutics, Inc. (CVKD) Misses Q2 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CVKD Hot Sheet
Join SI Premium – FREE
Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) reported Q2 EPS of ($1.87), $0.61 worse than the analyst estimate of ($1.26). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on Cadrenal Therapeutics, Inc. (CVKD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Red Violet (RDVT) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
